Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Grail stock craters as key NHS-Galleri trial fails to hit primary endpoint

Grail stock craters as key NHS-Galleri trial fails to hit primary endpoint

  • February 20, 2026

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service trial of its Galleri test missed its primary endpoint.

Leave A Comment

Fields (*) Mark are Required